Liraglutide Subcutaneous Injection 6 mg/mL solution Suppliers & Bulk Manufacturers

Available Forms: Subcutaneous injection/Pre filled Pen

Available Strengths: 6 mg/mL solution

Reference Brands: Victoza(US & EU)

Category: Diabetes

Liraglutide is a GLP-1 receptor agonist that mimics incretin hormones, stimulating insulin secretion, suppressing glucagon release, and delaying gastric emptying. Benefits include improved glycemic control in type 2 diabetes and weight loss (obesity management). It also reduces cardiovascular risk in high-risk patients. Administered once daily for convenience.

Product Description:

Liraglutide is a GLP-1 receptor agonist injected once daily. Novo Nordisk sells it as Victoza for type 2 diabetes, at up to 1.8 mg a day, and as Saxenda for weight management, at 3 mg a day. Both come as 6 mg/mL prefilled pens. In the US it carries a boxed warning about thyroid C-cell tumours seen in rodents.

Generic liraglutide

Liraglutide's main patents have expired in a number of markets, and generic versions are now approved. In the US, the first generic of Victoza was approved in December 2024 and the first generic of Saxenda in August 2025, and several more have followed. Novo Nordisk makes liraglutide by recombinant DNA technology in yeast; the US generics are synthetic peptide copies approved under the FDA's synthetic-peptide pathway, and regulators look closely at peptide-related impurities and immunogenicity risk.

Liraglutide API

Liraglutide is a modified peptide with a fatty-acid side chain. When you source the API, ask for the manufacturing route, a Certificate of Analysis covering assay and peptide-related impurities, the site's GMP certificate and a DMF where your market requires one. Manufacturers in India and China supply liraglutide API.

Pens are stored at 2 to 8 °C before first use and not frozen, so plan the cold chain. We also list liraglutide for weight management and semaglutide. Send us an RFQ with the product, quantity and destination market.